A recent survey reveals that almost 90% of U.S. adults are unaware of cardiovascular-kidney-metabolic syndrome, despite being at high risk. Learn about the interconnected risks and how to prevent this emerging health crisis.
New research reveals that drinking just one can of fizzy drinks daily can significantly increase the risk of developing a dangerous liver condition known as MASLD, challenging common beliefs about diet beverages.
A groundbreaking study reveals that adhering to the Mediterranean diet can significantly lower dementia risk, especially for those with a genetic predisposition to Alzheimer's. Discover how this diet can protect your brain health!
A groundbreaking study reveals that ultra-processed foods (UPFs) are sabotaging our metabolism, leading to weight gain despite exercise. Discover why the old adage of 'calories in, calories out' is misleading!
A groundbreaking study reveals that insulin resistance, measured by the triglyceride-glucose (TyG) index, can be a crucial indicator of rapid cognitive decline in Alzheimer's patients. Those with higher TyG levels face a fourfold increase in deterioration rates, prompting new intervention strategies.
In a bold move, a Turkish private equity firm has injected $39 million into a Harvard lab, aiming to pioneer new therapies for metabolic conditions. This unique financing approach could reshape academic funding in the future.
Research reveals that over 15 million people in the US, UK, Germany, and France are unaware they have metabolic dysfunction-associated steatotic liver disease, a condition linked to severe health risks. Experts call for increased screenings and diagnosis rates.
In an unprecedented medical achievement, a child with a rare genetic disorder receives a customized CRISPR gene therapy, paving the way for future treatments of similar conditions.
President Trump has nominated Dr. Casey Means, a holistic medicine doctor and wellness advocate, as Surgeon General, stirring debate over her credentials and alignment with federal health policies.
A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
